The median balanced superannuation fund rose an estimated 0.7% in February, as super funds continued to enjoy the market recovery as the COVID-19 vaccines rolled out, according to SuperRatings.
SuperRatings data also found the estimated median growth super fund rose 1.1%, while the median capital stable option fell 0.1%. Over the 2021 financial year to date, the median balanced option returned 9.7% which the research house said reflected the strength and speed of the post-pandemic recovery.
The median pension option in February returned 0.6% and 10.3% over the financial year to date. The median pension growth option returned 1.1% while the median capital stable option was down 0.2%.
SuperRatings executive director, Kirby Rappell, said: “Super has notched up another positive month, thanks to the vaccine narrative and the relative strength of Australia’s economic recovery, which has exceeded expectations.
“Markets are still bumpy and members should not be surprised to see the value of their super fluctuate over the course of 2021. With the severe shock of the pandemic now behind us, the challenge will be gradually transitioning away from government support programs and getting households and businesses back on a sustainable footing.
“Funds have shown they are able to adapt to rapid changes on these fronts, while also managing risks and attending to the needs of members through a challenging market. The pandemic period will serve as a masterclass in change management for superannuation that will lead to a more robust and agile industry in the long run.”
Jim Chalmers has defended changes to the Future Fund’s mandate, referring to himself as a “big supporter” of the sovereign wealth fund, amid fierce opposition from the Coalition, which has pledged to reverse any changes if it wins next year’s election.
In a new review of the country’s largest fund, a research house says it’s well placed to deliver attractive returns despite challenges.
Chant West analysis suggests super could be well placed to deliver a double-digit result by the end of the calendar year.
Specific valuation decisions made by the $88 billion fund at the beginning of the pandemic were “not adequate for the deteriorating market conditions”, according to the prudential regulator.